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Abstract 
 
Objective: To determine the cost-effectiveness, and the value of future research and 
implementation of mechanical thrombectomy, compared with standard treatment, from the 
perspective of the UK NHS and PSS. 
Design: We estimated the cost-effectiveness of mechanical thrombectomy, compared with standard 
practice over two time horizons: (i) 90-days – alongside the Pragmatic Ischaemic Stroke 
Thrombectomy Evaluation (PISTE) trial, using UK clinical and cost data, and (ii) lifetime – based on a 
decision-analytic model, using all available evidence. We performed a meta-analysis of seven clinical 
trials to estimate treatment effects. We used one-way and probabilistic sensitivity analysis to 
address uncertainty. Value of implementation analysis was used to estimate the potential value of 
implementing this endovascular thrombectomytreatment into routine clinical practice. 
Setting: UK healthcare system. 
Participants: Patients with acute ischaemic stroke eligible for mechanical thrombectomy. 
Intervention: Mechanical thrombectomy plus standard treatment, compared with standard 
treatment alone. 
Main outcome measure: Costs, quality-adjusted life-years gained (QALYs), cost-effectiveness. 
Results: Based on a 90-day time horizon, mechanical thrombectomy was not shown to be cost-
effective. However, over a lifetime horizon, this was no longer the case.  Mechanical thrombectomy 
plus IV-tPA, compared to IV-tPA alone, had an incremental cost of £7,649 and 2.207 QALYs and an 
incremental cost-effectiveness ratio of £3,466 per QALY gained. The net monetary benefit (health 
benefit in monetary terms) was £36,484 per patient. Based on the assumption of 51,404 eligible 
patients over a five year period, the value of implementation (at full implementation) was £1.3 
billion. We estimate the “break-even” value of implementation activity point at approximately 30% 
implementation. 
Conclusion: Our economic model suggests indicates that mechanical thrombectomy is cost-effective 
compared with standard care over a patient’s lifetime. On the assumption of full implementation 
being achieved throughout the UK healthcare system, we estimate that the population health 
benefits obtained from this treatment are greater than the cost of implementation.  
Trial registration: NCT01745692 
 
 
 
 
Background 
Until recently, thrombolysis, using intravenous tissue plasminogen activator (IV-tPA), has been the 
standard treatment for patients with ischaemic stroke who can be treated within 4.5 hours (1, 2). 
However, since 2015, evidence from eight randomised controlled trials (RCTs) have has 
demonstrated the superiority of mechanical thrombectomy, using second-generation devices, in the 
treatment of acute ischaemic stroke, in terms of the proportion of patients achieving favourable 
outcomes on the modified Rankin Scale (mRS) (3-10). In 2016, the National Institute for Health and 
Care Excellence (NICE) in the UK updated their guidelines for the treatment of acute ischaemic 
stroke to recommend the use of mechanical thrombectomy (2). In the following year, NHS England 
approved the use of mechanical thrombectomy in routine practice.  
 
Mechanical thrombectomy is an expensive and complicated highly skilled procedure undertaken 
predominantly in neurosciences centres. Several studies have assessed the cost-effectiveness of 
thrombectomy in combination with IV-tPA compared with IV-tPA alone, and concluded 
thrombectomy to be potentially cost-effective (11-18) and cost-saving (19-22). Two model-based 
cost-utility analyses, from the perspective of the UK NHS have been carried out (14, 21).  Based on 
meta-analysis of five RCTs, compared with IV-tPA, thrombectomy in combination with IV-tPA was 
associated with an additional £7,061 per quality adjusted life year gained(14). In the other study, 
based on data from an RCT conducted in the US and Europe (the SWIFT-PRIME trial), thrombectomy 
in combination with IV-tPA was reported to be associated with cost-savings of £33,190 per patient 
(21). However, the adoption and implementation of thrombectomy into routine practice will require 
additional investment in staff and capital equipment, and is also likely to require significant 
reorganisation of the healthcare system (23). Currently, one study has estimated the budget impact 
of adopting and implementing mechanical thrombectomy in Ireland (13). Based on treatment being 
delivered at two centres and treating 268 patients per year, the cost of implementation was 
estimated to be 7.2 million euros over five years.  
 
In adopting non-drug interventions into clinical practice, challenges to implementation may have an 
impact on cost-effectiveness. We conducted an economic evaluation to determine the cost-
effectiveness of mechanical thrombectomy (using stent retrievers) in combination with IV-tPA 
compared with IV-tPA alone, in patients with acute ischaemic stroke. In addition, we also estimated 
the monetary value of future research and the value of enhancing implementation of 
thrombectomy, using UK clinical and cost data. 
 
 Methods 
 
We estimated the cost-effectiveness of mechanical thrombectomy with IVT-tPA, compared with IV-
tPA alone over two time horizons: (i) 90-days – alongside the Pragmatic Ischaemic Stroke 
Thrombectomy Evaluation (PISTE) trial (9) and (ii) lifetime – based on a decision-analytic model. The 
lifetime model was used to conduct one-way and probabilistic sensitivity analysis. We also estimated 
the potential value of future research and the value of implementation initiatives to support the 
introduction of thrombectomy in routine practice. The analysis was carried out from the perspective 
of the National Health Service (NHS) and Personal and Social Services (PSS). Costs and health 
benefits were discounted at 3.5% in line with national guidelines (24). 
 
Within-trial analysis 
 
The PISTE trial was a multicentre, randomised controlled clinical trial comparing mechanical 
thrombectomy plus IV-tPA with IV-tPA alone, in patients who had acute ischaemic stroke with large 
artery occlusive anterior circulation stroke. Eligible patients were administered IV-tPA within 4.5 
hours of stroke. Patients receiving additional mechanical thrombectomy were treated within a target 
time of <90 mins from IV-tPA start to arterial puncture. The primary outcome was the proportion of 
patients achieving functional independence (mRS state 0-2) at 90 days.  
 
We conducted an economic evaluation alongside using data from the PISTE trial. Clinical outcome at 
90 days was measured by the modified Rankin Scale (mRS). The mRS scores were converted into 
health utilities using a conversion algorithm (25). Health utilities were used to calculate quality-
adjusted life-years (QALYs) over 90 days. Resource use estimates collected during the trial included 
hospital bed days and costs of treatments with IV-tPA and mechanical thrombectomy. Unit costs 
were obtained from the literature (14, 26, 27)and applied to resource use.  
 
Mean patient costs and QALYs were estimated by using a generalised linear model (GLM) and 
adjusting for potential confounding (28). We adjusted for the following covariates: age group, 
National Institutes of Health Stroke Scale (NIHSS) group, and baseline health utility (QALY estimates 
only).  The appropriate family for the GLM was selected based on the results of the modified Park’s 
test. Our final cost model was based on the log link and gamma family. Our final QALY model was 
based on the identity link and Gauss family. All analyses were conducted in Stata 12. Based on the 
estimation of the final statistical model, the total cost and QALY difference between groups is based 
on the marginal prediction. 
 
Cost-effectiveness was expressed as the incremental cost-effectiveness ratio (ICER). We employed 
the use of nonparametric bootstrapping to calculate 95% confidence intervals for our estimate of 
the difference in mean cost and QALYs between treatment groups. 
Lifetime economic model 
 
The economic model was based on a previously published model (14) and is in line with the clinical 
pathway described for patients with acute ischaemic stroke who are eligible for treatment with both 
IV-tPA and mechanical thrombectomy, according to the guidance set out by NICE (National Institute 
for Clinical Excellence 2016) (figure 1).  
 
Figure 1: Lifetime economic model (decision tree and Markov model) 
 
 
 
The first three months following stroke is represented by a decision tree. Following treatment, 
patients may result in one of three possible mutually exclusive health states state (mRS ≤2: 
functional independence; mRS 3-5: functional dependence; mRS 6: death). Subsequently, a four-
state Markov model is used to estimate costs and outcomes beyond three months. The model runs 
for 80 cycles of three months (20 years).  
 
We performed a meta-analysis to estimate the probabilities of patients resulting in the three mRS 
states using data from five RCT studies published in 2015 (3-7) and two recent trials – THRACE and 
PISTE trials (9, 10). Transition probabilities for the Markov model were sourced from the literature.  
Table 1 presents a list of parameters used in the lifetime model. 
 Table 1: Parameter used in the lifetime economic model 
 
Parameter Point estimate Probability 
distribution 
Source 
Decision tree    
mRS 0-2 (IV-tPA + Mech 
Throm) 
0.57 Conditional beta 
distribution 
Meta-analysis 
mRS 3-5 (IV-tPA + Mech 
Throm) 
0.27 Conditional beta 
distribution 
Meta-analysis 
mRS 6 (IV-tPA + Mech 
Throm) 
0.16 Conditional beta 
distribution 
Meta-analysis 
mRS 0-2 (IV-tPA only) 0.26 Conditional beta 
distribution 
Meta-analysis 
mRS 3-5 (IV-tPA only) 0.55 Conditional beta 
distribution 
Meta-analysis 
mRS 6 (IV-tPA only) 0.19 Conditional beta 
distribution 
Meta-analysis 
Markov model    
Year 1    
From independent (mRS 
0-2) to: 
   
mRS 0-2 0.955 Conditional beta 
distribution 
Davis (2012)  
mRS 3-5 0.024 Conditional beta 
distribution 
Davis (2012)  
recurrent stroke 0.013 Conditional beta 
distribution 
Davis (2012)  
dead 0.008 Conditional beta 
distribution 
Davis (2012)  
From dependent (mRS 
3-5) to: 
 Conditional beta 
distribution 
Davis (2012)  
mRS 0-2 0.029 Conditional beta 
distribution 
Davis (2012)  
mRS 3-5 0.919 Conditional beta 
distribution 
Davis (2012)  
recurrent stroke 0.013 Conditional beta 
distribution 
Davis (2012)  
dead 0.039 Conditional beta 
distribution 
Davis (2012)  
After year 1   Davis (2012)  
From independent (mRS 
0-2) to: 
  Davis (2012)  
mRS 0-2 0.979 Conditional beta 
distribution 
Davis (2012)  
mRS 3-5 0 Conditional beta 
distribution 
Davis (2012)  
recurrent stroke 0.013 Conditional beta 
distribution 
Davis (2012)  
dead 0.008 Conditional beta 
distribution 
Davis (2012)  
From dependent (mRS 
3-5) to: 
 Conditional beta 
distribution 
Davis (2012)  
mRS 0-2 0 Conditional beta 
distribution 
Davis (2012)  
mRS 3-5 0.948 Conditional beta 
distribution 
Davis (2012)  
recurrent stroke 0.013 Conditional beta 
distribution 
Davis (2012)  
dead 0.039 Conditional beta 
distribution 
Davis (2012)  
Recurrent stroke  Conditional beta 
distribution 
Davis (2012)  
(IV-tPA + Throm) mRS 0-
2 
0.867 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA + Throm) mRS 3-
5 
0.104 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA + Throm) 
recurrent stroke 
0 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA + Throm) dead 0.029 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA alone) mrs 0-2 0.834 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA alone) mrs 3-5 0.137 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA alone) recurrent 
stroke 
0 Conditional beta 
distribution 
Davis (2012)  
(IV-tPA alone) dead 0.029 Conditional beta 
distribution 
Davis (2012)  
Health utilities    
Independent 0.74 Beta distribution Dorman (2000) 
Dependent 0.38 Beta distribution Dorman (2000) 
Recurrent 0.34 Beta distribution Dorman (2000) 
Costs     
IV-TPA £1,919 Gamma 
distribution 
British National Formulary 
Thrombectomy £8,912 Gamma 
distribution 
Ganesalinham (2015), Davis (2012) 
first 3 months:  Gamma 
distribution 
 
Independent £7,302.83 Gamma 
distribution 
Ganesalinham (2015) 
Dependent £15,627.49 Gamma 
distribution 
Ganesalinham (2015) 
 
Cost-effectiveness was expressed as ICER and the incremental Net Monetary Benefit (NMB). The 
NMB is a measure of the health benefit, expressed in monetary terms, which incorporates the cost 
of the new strategy, the health gain obtained, and the societal willingness to pay for health gains. 
The NMB is calculated using the following formula: 
Incremental Net Monetary Benefit (NMB) = (ΔE*WTP) - ΔC 
E = effectiveness; WTP = willingness-to-pay threshold (£20,000 in the UK); C = cost 
Uncertainty 
 
Uncertainty around the parameter estimates used in our model was fully characterised and 
propagated through to the model results by conducting probabilistic sensitivity analysis (PSA). This 
was done by defining parameter values using distributions rather than point estimates. The model 
was then run 5,000 times with a value randomly drawn from the assigned probability distribution. 
This produced a distribution of model outputs which was represented visually on the cost-
effectiveness plane. A cost-effectiveness acceptability curve (CEAC) was used to represent the 
probability that an intervention would be cost-effective compared to the control group at a range of 
willingness-to-pay thresholds (λ). 
 
We conducted one-way sensitivity analysis on the key parameters driving the cost-effectiveness 
estimate of mechanical thrombectomy in our model. We tested: the cost of the mechanical 
thrombectomy procedure; the health utility associated with functional independence, dependence 
and death; the proportion of patients achieving functional independence, dependence and death, 
following treatment with mechanical thrombectomy or IV-tPA alone. We tested the impact on the 
model’s estimate of cost-effectiveness (i.e. the ICER) of varying each of these parameters individually 
by +/- 20% Further details are given in the appendix. 
 
Value of information 
 
Value of information analysis on the expected value of perfect information (EVPI) was carried out to 
quantify the potential value of further research based on the difference between the expected 
health benefits (NMB) with perfect information and with existing information. The EVPI represents 
the amount a decision maker should be willing to pay to eliminate uncertainty regarding which 
intervention is the best option. This uncertainty is characterised in the model in terms of parameter 
uncertainty and is addressed through the use of PSA which produces a distribution of outcomes, in 
terms of costs and QALYs, for each treatment. The difference between the NMB, based on a decision 
made with perfect information (i.e. no uncertainty) and with current information, represents the 
EVPI. 
 
It has been estimated that approximately 11,000 patients with acute ischaemic stroke are eligible for 
mechanical thrombectomy per year in the UK (29-31). For the analysis, we assumed the effective 
population (discounted population) which stands to benefit from this treatment to be 51,404 
patients over a five year period, and that the lifetime of the new technology to be five years.  
 
Value of implementation 
 
We calculated the value of implementation as the value of perfect implementation minus the cost of 
implementation (32), measured over a five year time horizon. We estimate the maximum potential 
value of implementation as the net monetary benefit of achieving 100% implementation across the 
UK (51,404 patients over five years). We then subtracted from this the cost of 29 comprehensive 
stroke centres across the UK necessary to perform this procedure. We included costs of ongoing 
staff salaries and initial set-up costs - such as training and equipment (full details are given in the 
appendix). We also estimate the “break-even” point at which the NMB obtained from the proportion 
of eligible patients treated is equal to the cost of implementation. 
 
Results 
Within-trial analysis 
The results of the within-trial analysis found that mechanical thrombectomy plus IV-tPA, compared 
to IV-tPA alone, had a total cost of £17,156 compared with £11,949. Over the course of the trial (90 
days), the QALYs gained in the intervention group were 0.142, compared with 0.117 in the control 
group. This equates to an incremental cost of £5,207 and 0.025 QALYs associated with the addition 
of mechanical thrombectomy to standard treatment and an ICER of £205,279 per QALY gained. The 
bootstrapped mean cost difference between groups was £5,207 (95% CI: -£1,458, £11,873) and the 
mean QALY difference was 0.026 (95% CI: -0.008, 0.059). 
Lifetime economic model 
The results of the economic model found that mechanical thrombectomy plus IV-tPA, compared to 
IV-tPA alone, had a total cost of £46,684 compared with £39,035 (table 2). Over a lifetime horizon, 
the QALYs gained in the intervention group were 7.614, compared with 5.408 in the control group. 
This equates to an incremental cost of £7,649 and 2.207 QALYs associated with the addition of 
mechanical thrombectomy to standard treatment and an incremental cost-effectiveness ratio of 
£3,466 per QALY gained and an incremental NMB of £36,484 per patient. 
 
 
 
 
 
Table 2: Results of lifetime economic model 
 
Treatment Cost (£) QALYs 
gained 
Incremental 
cost (£) 
Incremental 
QALYs 
gained 
Incremental 
cost/QALY 
gained (ICER) 
Incremental 
NMB 
IV-tPA £39,035 5.408     
IV-tPA + 
Mechanical 
thrombectomy 
£46,684 7.614 £7,649 2.207 £3,466 £36,484 
 
Probabilistic sensitivity analysis 
 
The cost-effectiveness plane shows the results of running the model 5,000 times and recording the 
difference in cost and effectiveness between the mechanical thrombectomy and IV-tPA (figure 2). 
Although most data points are observed in the upper right quadrant of the plane (representing the 
scenario of ‘more costly and more effective’), there is considerable uncertainty surrounding the 
extent and existence of the additional expected costs and the existence and extent of the additional 
expected QALYs. 
 
 
 
 
 
 
 
 
 
Figure 2: Cost effectiveness plane 
 
The cost-effectiveness acceptability curve (CEAC) shows the probability of mechanical 
thrombectomy being cost-effective for different levels of willingness-to-pay thresholds, compared 
with IV-tPA alone (figure 3). The CEAC shows that, at a willingness-to-pay threshold of £20,000 per 
QALY gained, mechanical thrombectomy has a 76% probability of being cost-effective, compared 
with IV-tPA alone. 
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Figure 3: Cost-effectiveness acceptability curve 
 
One-way sensitivity analysis 
 
We conducted one-way sensitivity analysis on the key parameters driving the cost-effectiveness 
estimate of mechanical thrombectomy in our model. Our results showed that varying all of these key 
parameters within our model had no impact on the decision problem, i.e. all ICER estimates remain 
below £20,000 per QALY. The parameter which had the greatest negative impact on cost-
effectiveness (i.e. increased the ICER) was the proportion of patients achieving functional 
independence (mRS 0-2) after receiving mechanical thrombectomy.  
 
Value of information 
 
The expected value of perfect information per patient affected by the decision is estimated at 
£3,178 per person. Based on our assumptions of 11,000 eligible patients per year over a five-year 
lifetime of this technology, at a willingness-to-pay of £20,000 per QALY gained, this equates to an 
expected value of perfect information of £163 million over a five year period for the UK population 
(figure 5).  
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Figure 5: The expected value of perfect information (population level) 
 
 
Value of implementation 
 
We estimate the value of perfect implementation as the net monetary benefit from mechanical 
thrombectomy (£36,484 per person) multiplied by the effective population (51,404). This implies 
that the expected value of perfect implementation in UK would be £1.7 billion. We estimate a cost of 
£413 million to implement this procedure across the UK (a full breakdown of the cost calculation is 
given in the appendix). This suggests an expected value of implementation of £1.3 billion over five 
years. We estimate the “break-even” value of implementation activity point at approximately 30% 
implementation (approx. 3,084 patients per year). Below this point, the cost of implementing 
mechanical thrombectomy into routine practice is expected to be greater than the benefit, in NMB 
terms. 
 
Conclusion 
 
Based on a lifetime horizon, our economic model suggests that mechanical thrombectomy is cost-
effective compared with standard care.  Further research costing more than £163 million would not 
be considered a cost-effective use of resources. This is because the return of the investment from 
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further research, in terms of the costs and/or health benefits gained from choosing an alternative 
strategy based on the new evidence, is expected to be no higher than the figure of £163 million. 
On the assumption of full implementation being achieved throughout the UK healthcare system, we 
estimate that the value of implementation is greater than the cost of implementation. We find that 
this result holds for any level of implementation greater than approximately 30%. 
 
Discussion 
 
Our results suggest indicate that mechanical thrombectomy, in addition to IV-tPA, compared with IV-
tPA alone, is likelymeets standard criteria  to be considered a cost-effective use of resources in a UK 
health service setting. The results of our study are consistent with other UK economic evaluations 
which suggest the cost-effectiveness of mechanical thrombectomy over a patient’s lifetime 
perspective (14, 21). One UK study found mechanical thrombectomy to be cost-saving.  This is 
primarily driven by the assumption of higher long-term care costs associated with disability after 
stroke patients and the savings resulting from greater the avoidance of disability due to treatment 
with mechanical thrombectomy.  
 
Our results suggest that the use of mechanical thrombectomy is unlikely to be cost-effective over a 
90-day time horizon, based on data from the UK-based (PISTE trial). This is due to a very small 
difference in health benefits between the two treatments, the incremental QALY gain was 0.025.  
The incremental cost of mechanical thrombectomy over a 90-day period was £5,207, compared with 
£7,649 over a lifetime horizon. However, the QALY gain over a 90-day horizon was 0.025 QALYs, 
compared with 2.207 QALYs over a lifetime horizon. This implies that, over a lifetime horizon, there 
is a proportionally greater increase in QALYs than costs. 
 
Our lifetime cost-effectiveness model used clinical evidence from seven RCTs of mechanical 
thrombectomy (using second generation stent retrievers), but did not consider subsequent trials 
indicating benefit from mechanical thrombectomy in patients presenting in later time windows (6-24 
hours) based on additional imaging selection criteria (30, 31). In order to estimate the cost of 
routinely providing mechanical thrombectomy across the UK, it was necessary to make some 
assumptions (see appendix). In terms of staffing costs, our results are likely to be an overestimate. 
This is because we have chosen to provide the cost of a full-time equivalent for some staff 
(interventional neuroradiology, anaesthetist) to reflect the need to have these staff available on 
demand over a 24 hour service. In practice it is likely that a proportion of these staff will spend their 
time on activities unrelated to thrombectomy.  In addition, we have included the full cost of an 
angiography suite required to undertake the procedure to reflect the initial set-up costs required, 
however, in practice this equipment will be available for other activities and hence not all costs 
associated with the suite will be attributable to thrombectomy. 
 
The ability to identify patients mostly likely to benefit from mechanical thrombectomy and to triage 
these patients from stroke onset to initiation of treatment within the required time period presents 
a challenge. To meet this challenge, significant system reorganisation will be required (23). The 
clinical trial evidence relates to patients which who were predominantly able to receive treatment 
within 6 8 hours from stroke onset, a small minority being treated beyond 6 hours in the two trials 
with longer time windows (ESCAPE 12 hours and REVASCAT 8 hours). Patient level meta-analysis 
confirms steeply declining benefit with later treatment even within the first 6 hours.(33) As such, 
strategies aimed at minimising door-to-needle times are recommended. The role of imagining in the 
early identificationselection of patients mostly likely to benefit fromfor mechanical thrombectomy, 
or to benefit from treatmentas undertaken in  both trials of thrombectomy beyond the currently 
recommended 6 hour time window,(34, 35) is a topic of ongoing researchremains uncertain for 
those treated within the first 6 hours, since only two trials mandated similar selection criteria.(36, 
37) (PRACTICE) (38). The role of regional hospitals (“primary stroke centres”), unable to deliver 
mechanical thrombectomy, in the early administration of IV-tPA prior to transfer to a comprehensive 
stroke centre - the so called “drip and ship” model vs. the “mothership” model - remains 
unresolvedis likely to require local planning dependent on service characteristics and transport 
networks (39). The need to maintain a minimum institutional and individual workload to maintain 
skills would likely pose a challenge to regional hospitals. Further research in these areas will 
contribute to the discussion around optimal system organisation and will impact on the cost-
effectiveness of mechanical thrombectomy that will should expect tobe observed in routine practice. 
However, tThe results of our implementation analysis suggests that the cost-effectiveness of 
mechanical thrombectomy in practice is not contingent on achieving full implementation. Indeed, 
our results suggest that any level of implementation greater than 30% is likely to be a cost-effective 
use of resources.  
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